Results & Financial lifeHealthcare - Pharma - Biotech
bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
10/11/2026 06:59
AMFImmediate publication
Marcy-l’Étoile (France), November 10th, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VITEK® PRO has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the CE marking under IVDR*. This innovative system for microbial…
bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Marcy-l’Étoile (France), November 10th, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that VITEK® PRO has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the CE marking under IVDR*. This innovative system for microbial identification (ID) and antimicrobial susceptibility testing (AST) supports clinical laboratories in diagnosing infectious diseases and advancing Antimicrobial Stewardship (AMS) efforts. The commercial launch of the solution is planned to begin in the first quarter of 2027.
Ranked among the top global public health threats by the World Health Organization,1 antimicrobial resistance (AMR) is estimated to cause 1.27 million deaths in a single year.2 Accurate identification of microorganisms and timely antimicrobial susceptibility testing are critical for supporting clinical decision-making, improving patient management, and strengthening antimicrobial stewardship (AMS) programs.
Building on more than 35 years of expertise in ID/AST technologies, bioMérieux has developed VITEK® PRO, an easy-to-operate and highly reliable solution for routine microbiology testing. Using a single platform, laboratories can identify the microorganism responsible for an infection and determine antimicrobial susceptibility, helping clinicians select the most appropriate antibiotic therapy. By providing timely results, VITEK® PRO enables clinical decision-making that supports better patient outcomes and contributes to global efforts to combat antimicrobial resistance.
VITEK® PRO offers a flexible capacity design for seamless expansion that can adapt to current and future needs of medium and high volume laboratories. Configured for high efficiency, this instrument helps laboratories improve productivity in increasingly resource-constrained environments, while maintaining high confidence in diagnostic results. VITEK® PRO combines advanced workflow automation and modern digital capabilities, with a broad antimicrobial testing menu meeting local epidemiology requirements.
"Antimicrobial resistance continues to threaten the foundations of modern medicine. Rapid and accurate antimicrobial susceptibility testing is essential to ensure patients receive the most appropriate treatment as early as possible. With VITEK® PRO, we are bringing together decades of expertise in automated microbiology with significant innovations in workflow, software architecture, connectivity, and user experience. This new platform reinforces bioMérieux's commitment to supporting healthcare professionals worldwide in the fight against antimicrobial resistance," stated Céline Roger-Dalbert, Executive Vice President, Research and Development, bioMérieux.